NCT01352520View on ClinicalTrials.gov

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
CD-30 Positive Anaplastic Large T-cell Cutaneous LymphomaLymphoma, Primary Cutaneous Anaplastic Large CellLymphomatoid PapulosisMycosis FungoidesSkin LymphomaCutaneous LymphomasLymphomaHematologic Disorder
Interventions
DRUG

SGN-35

1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER